약물감시 시장 규모, 점유율 및 동향 분석 보고서 : 제품수명주기별, 서비스 프로바이더별, 유형별, 치료 영역별, 프로세스 플로우별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Pharmacovigilance Market Summary

The global pharmacovigilance market size was valued at USD 8.6 billion in 2025 and is projected to grow from USD 9.2 billion in 2026 to USD 13.5 billion by 2033, growing at a CAGR of 5.6% from 2026 to 2033. America dominated the market in 2025 and held the largest share of 31.7%. The rising incidence of Adverse Drug Reactions (ADRs) owing to drug abuse and the prevalence of diseases that require a combination of drugs are the major growth drivers for the market.

In addition, an upward shift in the production of novel drugs and the presence of stringent government regulatory frameworks for drug safety are significantly boosting the market growth. For instance, the U.S. FDA and the European Medicines Agency (EMA) issue regulatory guidelines for all phases of clinical trials. Moreover, advancements in the development of ADR databases and information systems have enabled accurate reporting of information, which can be further utilized by research professionals for prospective clinical studies, thereby fueling overall growth.

Global Pharmacovigilance Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmacovigilance market report based on service provider, product life cycle, type, process flow, therapeutic area, end use, and region:

• Product Life Cycle Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV
• Service Provider Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• In-house
• Contract Outsourcing
• Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining
• End Use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Pharmaceuticals
• Biotechnology Companies
• Medical Device Manufacturers
• Others
• Therapeutic Area Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others
• Process Flow Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Case Data Management
  • Case Logging
  • Case Data Analysis
• Medical Reviewing & Reporting
• Signal Detection
  • Adverse Event Logging
  • Adverse Event Analysis
  • Adverse Event Review & Reporting
• Risk Management System
  • Risk Evaluation System
  • Risk Mitigation System
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Life Cycle
  • 1.2.2. Service Provider
  • 1.2.3. Type
  • 1.2.4. Process Flow
  • 1.2.5. Therapeutic area
  • 1.2.6. End use
  • 1.2.7. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
    • 1.5.4.1. Details of Primary Research
    • 1.5.4.2. Data for primary interviews in North America
    • 1.5.4.3. Data for Primary Interviews in Europe
    • 1.5.4.4. Data for Primary Interviews in APAC
    • 1.5.4.5. Data for Primary Interviews in Latin America
    • 1.5.4.6. Data for Primary Interviews in MEA
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Report Objectives
  • 1.10.1. Objective-1
  • 1.10.2. Objective-2

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
  • 2.2.1. Segment Snapshot (Product Life Cycle & Type)
  • 2.2.2. Segment Snapshot (Process Flow & Therapeutic Area)
  • 2.2.3. Segment Snapshot (End Use)
  • 2.2.4. Competitive Landscape Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing drug consumption and drug development rates
    • 3.2.1.2. Increasing incidence of ADR and drug toxicity
    • 3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
    • 3.2.1.4. Increasing externalization of clinical trial studies by large
    • 3.2.1.5. Increasing Regulatory Burden on Manufacturers
    • 3.2.1.6. Introduction of technologically advanced software services
      • 3.2.1.6.1.Key focus areas for the pharmaceutical/healthcare companies
      • 3.2.1.6.2.Adoption of technological advancements in the life sciences industry
      • 3.2.1.6.3.Published Survey insights - related to the adoption of pharmacovigilance automation
    • 3.2.1.7. Rising investment on R&D by healthcare companies
    • 3.2.1.8. Partnerships and collaborations between market players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Shortage of skilled labor
    • 3.2.2.2. Expensive technology for small- and mid-sized players
    • 3.2.2.3. Lack of recognition
    • 3.2.2.4. Scarcity of integration standards
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
• 3.3. Porter's Five Forces Analysis
  • 3.3.1.1. Supplier power
  • 3.3.1.2. Buyer power
  • 3.3.1.3. Substitution threat
  • 3.3.1.4. Threat of new entrant
  • 3.3.1.5. Competitive rivalry
• 3.4. PESTLE Analysis
• 3.5. Value Chain Analysis
  • 3.5.1. Preclinical
  • 3.5.2. Clinical
  • 3.5.3. PMA
• 3.6. Mapping of Life Cycle Against Service Offering and Their Demand
• 3.7. Regulatory Framework
  • 3.7.1. List of regulatory bodies by Country
• 3.8. Pricing Models
  • 3.8.1. Drug safety budget allocation by activities
  • 3.8.2. By development phase
  • 3.8.3. By therapeutic area
  • 3.8.4. Pricing level
    • 3.8.4.1. Project management
    • 3.8.4.2. Case processing
    • 3.8.4.3. ADR Reporting
    • 3.8.4.4. Medical writing
    • 3.8.4.5. Drug safety management
• 3.9. Technology Timeline Overview
  • 3.9.1. Changing Technology & Adoption
  • 3.9.2. Current Technology Landscape of PV
  • 3.9.3. IQVIA's AI-Driven Transformation in Pharmacovigilance
  • 3.9.4. Tech Mahindra's AI-Driven Pharmacovigilance Solution in
  • 3.9.5. The evolving PV workload with AI assistance
  • 3.9.6. Social Media
    • 3.9.6.1. Literature screening
    • 3.9.6.2. Automation and AI
    • 3.9.6.3. Big data analytics in PV
• 3.10. Market Trend
  • 3.10.1. Scaling of resources
  • 3.10.2. Automation in Pharmacovigilance
• 3.11. Impact of Inflation
• 3.12. Case Studies
  • 3.12.1. Potential Customers
  • 3.12.2. Notable Use Cases
  • 3.12.3. Case Study 1
    • 3.12.3.1. Part 1
    • 3.12.3.2. Part 2
  • 3.12.4. Case Study 2
  • 3.12.5. Case Study 3
  • 3.12.6. Case Study 4

Chapter 4. Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

• 4.1. Product Life Cycle Segment Dashboard
• 4.2. Product Life Cycle Market Share Movement Analysis, 2025 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Product Life Cycle, 2021 to 2033 (USD Million/Billion)
  • 4.3.1. Preclinical
    • 4.3.1.1. Preclinical market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.3.2. Phase I
    • 4.3.2.1. Phase I market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.3.3. Phase II
    • 4.3.3.1. Phase II market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.3.4. Phase III
    • 4.3.4.1. Phase III market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.3.5. Phase IV
    • 4.3.5.1. Phase IV market estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. Pharmacovigilance Market Service Provider Estimates & Trend Analysis

• 5.1. Service Provider Dashboard
• 5.2. Service Provider Market Share Movement Analysis, 2025 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Service Provider, 2021 to 2033 (USD Million/Billion)
• 5.4. In House
  • 5.4.1. In-house market, 2021 - 2033 (USD Million/Billion)
• 5.5. Contract Outsourcing
  • 5.5.1. Contract Outsourcing market, 2021 - 2033 (USD Million/Billion)

Chapter 6. Pharmacovigilance Market: Type Estimates & Trend Analysis

• 6.1. Type Segment Dashboard
• 6.2. Type Market Share Movement Analysis, 2025 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million/Billion)
• 6.4. Spontaneous Reporting
  • 6.4.1. Spontaneous Reporting market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 6.5. Intensified ADR Reporting
  • 6.5.1. Intensified ADR Reporting market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 6.6. Targeted Spontaneous Reporting
  • 6.6.1. Targeted spontaneous reporting market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 6.7. Cohort Event Monitoring (CEM)
  • 6.7.1. CEM market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 6.8. EHR Mining
  • 6.8.1. EHR Mining market estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

• 7.1. Process Flow Segment Dashboard
• 7.2. Process Flow Market Share Movement Analysis, 2025 & 2033
• 7.3. Market Size & Forecasts and Trend Analysis, by Process Flow, 2021 to 2033 (USD Million/Billion)
• 7.4. Case data management
  • 7.4.1. Case data management market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 7.4.1.1. Case logging
      • 7.4.1.1.1.Case logging market, 2021 - 2033 (USD Million/Billion)
    • 7.4.1.2. Case data analysis
      • 7.4.1.2.1.Case data analysis market, 2021 - 2033 (USD Million/Billion)
• 7.5. Medical reviewing and reporting
  • 7.5.1.1. Medical reviewing and reporting market, 2021 - 2033 (USD Million/Billion)
• 7.6. Signal detection
  • 7.6.1. Signal detection market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 7.6.1.1. Adverse Event Logging
      • 7.6.1.1.1.Adverse event logging market, 2021 - 2033 (USD Million/Billion)
    • 7.6.1.2. Adverse Event Analysis
      • 7.6.1.2.1.Adverse Event Analysis market, 2021 - 2033 (USD Million/Billion)
    • 7.6.1.3. Adverse Event Review & Reporting
      • 7.6.1.3.1.Adverse Event Review & Reporting market, 2021 - 2033 (USD Million/Billion)
• 7.7. Risk Management System
  • 7.7.1. Risk Management System market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 7.7.1.1. Risk Evaluation System
      • 7.7.1.1.1.Risk Evaluation market, 2021 - 2033 (USD Million/Billion)
    • 7.7.1.2. Risk Mitigation System
      • 7.7.1.2.1.Risk Mitigation market, 2021 - 2033 (USD Million/Billion)

Chapter 8. Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

• 8.1. Therapeutic Area Segment Dashboard
• 8.2. Therapeutic Area Market Share Movement Analysis, 2025 & 2033
• 8.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million/Billion)
• 8.4. Oncology
  • 8.4.1. Oncology market, 2021 - 2033 (USD Million/Billion)
• 8.5. Neurology
  • 8.5.1. Neurology market, 2021 - 2033 (USD Million/Billion)
• 8.6. Cardiology
  • 8.6.1. Cardiology market, 2021 - 2033 (USD Million/Billion)
• 8.7. Respiratory Systems
  • 8.7.1. Respiratory Systems market, 2021 - 2033 (USD Million/Billion)
• 8.8. Others
  • 8.8.1. Other market, 2021 - 2033 (USD Million/Billion)

Chapter 9. Pharmacovigilance Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market: Key Takeaways
• 9.3. North America
  • 9.3.1. North America Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamic
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive insights
    • 9.3.2.4. U.S. Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamic
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive insights
    • 9.3.3.4. Canada Pharmacovigilance market estimates and forecasts, 2021 - 2033
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamic
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive insights
    • 9.3.4.4. Mexico Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 9.4. Europe
  • 9.4.1. Europe Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamic
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive insights
    • 9.4.2.4. Germany Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.3. UK
    • 9.4.3.1. Key country dynamic
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive insights
    • 9.4.3.4. UK Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamic
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive insights
    • 9.4.4.4. France Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamic
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive insights
    • 9.4.5.4. Italy Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamic
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive insights
    • 9.4.6.4. Spain Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.7. Russia
    • 9.4.7.1. Key country dynamic
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive insights
    • 9.4.7.4. Russia Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamic
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive insights
    • 9.4.8.4. Denmark Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.9. Sweden
    • 9.4.9.1. Key country dynamic
    • 9.4.9.2. Regulatory framework
    • 9.4.9.3. Competitive insights
    • 9.4.9.4. Sweden Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.10. Norway
    • 9.4.10.1. Key country dynamic
    • 9.4.10.2. Regulatory framework
    • 9.4.10.3. Competitive insights
    • 9.4.10.4. Norway Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.2. Japan
    • 9.5.2.1. Key country dynamic
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive insights
    • 9.5.2.4. Japan Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.3. China
    • 9.5.3.1. Key country dynamic
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive insights
    • 9.5.3.4. China Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamic
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive insights
    • 9.5.4.4. India Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamic
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive insights
    • 9.5.5.4. South Korea Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamic
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive insights
    • 9.5.6.4. Australia Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamic
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive insights
    • 9.5.7.4. Thailand Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 9.6. Latin America
  • 9.6.1. Latin America Pharmacovigilance Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamic
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive insights
    • 9.6.2.4. Brazil Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 9.6.2.5. (USD Million/Billion)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamic
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive insights
    • 9.6.3.4. Argentina Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 9.7. MEA
  • 9.7.1. MEA Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamic
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive insights
    • 9.7.2.4. South Africa Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamic
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive insights
    • 9.7.3.4. Saudi Arabia Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamic
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive insights
    • 9.7.4.4. UAE Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamic
    • 9.7.5.2. Regulatory framework
    • 9.7.5.3. Competitive insights
    • 9.7.5.4. Kuwait Pharmacovigilance market estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 10. Pharmacovigilance Market: Competitive Analysis

• 10.1. Market Participant Categorization
• 10.2. Company Market Position Analysis
• 10.3. Company Market Share Analysis, 2025
• 10.4. Competitive Factors and Strategies
  • 10.4.1. Increasing Strategic Collaborations and Product Launches
  • 10.4.2. Strategic Government initiatives, including collaborations
  • 10.4.3. Competitors increased PV Awareness programs
  • 10.4.4. Competitors increased collaboration and outsourcing of operations
  • 10.4.5. Consolidation Trends

Chapter 11. Competitive Landscape

• 11.1. Company Profiles
  • 11.1.1. Accenture
    • 11.1.1.1. Overview
    • 11.1.1.2. Financial performance
    • 11.1.1.3. Product benchmarking
    • 11.1.1.4. Strategic initiatives
  • 11.1.2. IQVIA Inc.
    • 11.1.2.1. Overview
    • 11.1.2.2. Financial performance
    • 11.1.2.3. Product benchmarking
    • 11.1.2.4. Strategic initiatives
  • 11.1.3. Cognizant
    • 11.1.3.1. Overview
    • 11.1.3.2. Financial performance
    • 11.1.3.3. Product benchmarking
    • 11.1.3.4. Strategic initiatives
  • 11.1.4. Clinquest Group B.V. (Linical Americas)
    • 11.1.4.1. Overview
    • 11.1.4.2. Financial performance
    • 11.1.4.3. Product benchmarking
    • 11.1.4.4. Strategic initiatives
  • 11.1.5. IBM
    • 11.1.5.1. Overview
    • 11.1.5.2. Financial performance
    • 11.1.5.3. Product benchmarking
    • 11.1.5.4. Strategic initiatives
  • 11.1.6. Laboratory Corporation of America Holdings
    • 11.1.6.1. Overview
    • 11.1.6.2. Financial performance
    • 11.1.6.3. Product benchmarking
    • 11.1.6.4. Strategic initiatives
  • 11.1.7. ArisGlobal
    • 11.1.7.1. Overview
    • 11.1.7.2. Financial performance
    • 11.1.7.3. Product benchmarking
    • 11.1.7.4. Strategic initiatives
  • 11.1.8. Capgemini
    • 11.1.8.1. Overview
    • 11.1.8.2. Financial performance
    • 11.1.8.3. Product benchmarking
    • 11.1.8.4. Strategic initiatives
  • 11.1.9. ITClinical
    • 11.1.9.1. Overview
    • 11.1.9.2. Financial performance
    • 11.1.9.3. Products & Services benchmarking
    • 11.1.9.4. Strategic initiatives
  • 11.1.10. ICON plc.
    • 11.1.10.1. Overview
    • 11.1.10.2. Financial performance
    • 11.1.10.3. Product benchmarking
    • 11.1.10.4. Strategic initiatives
  • 11.1.11. TAKE Solutions Limited
    • 11.1.11.1. Overview
    • 11.1.11.2. Financial performance
    • 11.1.11.3. Product benchmarking
    • 11.1.11.4. Strategic initiatives
  • 11.1.12. Parexel International (MA) Corporation
    • 11.1.12.1. Overview
    • 11.1.12.2. Financial performance
    • 11.1.12.3. Product benchmarking
    • 11.1.12.4. Strategic initiatives
  • 11.1.13. Wipro
    • 11.1.13.1. Overview
    • 11.1.13.2. Financial performance
    • 11.1.13.3. Product benchmarking
    • 11.1.13.4. Strategic initiatives
  • 11.1.14. United BioSource LLC
    • 11.1.14.1. Overview
    • 11.1.14.2. Financial performance
    • 11.1.14.3. Product benchmarking
    • 11.1.14.4. Strategic initiatives
  • 11.1.15. BioClinica Inc. (Clario)
    • 11.1.15.1. Overview
    • 11.1.15.2. Financial performance
    • 11.1.15.3. Product benchmarking
    • 11.1.15.4. Strategic initiatives
  • 11.1.16. ClinChoice (formerly FMD K&L)
    • 11.1.16.1. Overview
    • 11.1.16.2. Financial performance
    • 11.1.16.3. Product benchmarking
    • 11.1.16.4. Strategic initiatives

Chapter 12. Winning Strategies

• 12.1. Key Winning / Scoring Criteria
  • 12.1.1. By Categories
    • 12.1.1.1. Pharmaceuticals
    • 12.1.1.2. Biotech companies
    • 12.1.1.3. Medical device companies
  • 12.1.2. Key Vendor Selection Factors
    • 12.1.2.1. By Category
    • 12.1.2.2. BY Company size
      • 12.1.2.2.1.1. Key Takeaways

Chapter 13. Switching Cost Analysis